S

Synlogic
D

SYBX

1.33000
USD
-0.05
(-3.62%)
مغلق
حجم التداول
0
الربح لكل سهم
-7
العائد الربحي
-
P/E
-1
حجم السوق
15,555,825
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ACAD
    -0.350
    (-1.73%)
    19.940 USD
    A
    ACRS
    -0.08000
    (-3.45%)
    2.24000 USD
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    A
    AMRN
    -0.00130
    (-0.22%)
    0.58930 USD
    A
    ARDX
    -0.65000
    (-11.39%)
    5.05500 USD
    A
    AVDL
    -0.05500
    (-0.65%)
    8.41000 USD
    BMY
    BMY
    0.050
    (0.09%)
    55.840 USD
    M
    MYGN
    -0.790
    (-5.27%)
    14.190 USD
    المزيد
الأخبار
المقالات

العنوان: Synlogic

القطاع: Healthcare
الصناعة: Biotechnology
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformativetreatments for serious diseases.